Eur J Nucl Med Mol Imaging (2017) 44:1663–1670 DOI 10.1007/s00259-017-3751-z ORIGINAL ARTICLE Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer 1 1 1 2 Axel Bräuer & Lena Sophie Grubert & Wolfgang Roll & Andres Jan Schrader & 1 2 1 Michael Schäfers & Martin Bögemann & Kambiz Rahbar Received: 12 May 2017 /Accepted: 1 June 2017 /Published online: 17 June 2017 Springer-Verlag GmbH Germany 2017 Abstract dose 6.11 GBq, IQR 5.9–6.3 GBq). The median follow-up Purpose Radioligand therapies targeting prostate-specific was 24 weeks (IQR 15–36 weeks). Follow-up data for at least membrane antigen (PSMA) have been established for the 12 weeks (PCWG3) were available in 76% (45) of the pa- treatment of metastasized castration-resistant prostate cancer tients. For outcome results data from all patients treated with (mCRPC) in the last decade and show promising response at least one cycle were analysed. A decline in prostate-specific rates and a favourable toxicity profile. The aim of this study antigen (PSA) of ≥50% occurred in 53%, and a decline in PSA was to evaluate the overall survival (OS) and to identify pa- of any amount in 91% of patients. The estimated median OS rameters predicting outcome in
European Journal of Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Jun 17, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera